Fundz
Real-time · AI · Cross-signal

Royalty Pharma plc just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Royalty Pharma plc, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement for Yorvipath

Sep 03, 2024•over 1 year ago

Contract Type

agreement

New YorkBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Royalty Pharma and Ascendis Pharma A/S have entered into a $150 million royalty funding agreement. This funding agreement is based on U.S. net sales of Yorvipath, representing an important advancement in treating hypoparathyroidism in adults.

Company Information

Company

Royalty Pharma plc

Location

New York, New York, United States

About

Royalty Pharma plc is a pharmaceutical company with a robust EBITDA of $2.57 billion and market capitalization of $11.64 billion. It has recently announced the acquisition of its external manager, RP Management, LLC, in a strategic move to generate significant cost savings and enhance shareholder value. The company is committed to strengthening shareholder relationships, improving corporate governance, and ensuring management continuity.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Royalty Pharma plc's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months